A prospective follow-up study of 39 vaginally born low risk preterm (less than 37 weeks of gestation) and ten term control infants was carried out to estimate psychological and neurodevelopmental outcome at four years of age in relation to conceptual age and fetal acidosis at birth. The patients were divided into two groups: infants born after 29-33 weeks gestation (Group I) and those born after 34-36 weeks gestation (Group II), with or without fetal acidosis, i.e. a fetal scalp pH below or above 7.20. Acidotic infants normalized within the first hour after birth. Marked low and high performance groups for intellectual performance and hearing and vision tests were discernable within the first two years. The language performance of preterm infants was delayed compared to infants born at term, especially in Group II infants. At four years of age, a higher number of Group II infants had psychomotor developmental problems; whereas, neurological handicaps were more frequent in Group I infants with fetal acidosis. This indicates that re-evaluation of neurodevelopmental outcome is needed at a later age, e.g. six years of age, in preterm infants after low risk deliveries.

Download full-text PDF

Source
http://dx.doi.org/10.1515/jpme.1987.15.1.61DOI Listing

Publication Analysis

Top Keywords

low risk
12
preterm infants
12
weeks gestation
12
years age
12
fetal acidosis
12
group infants
12
infants
10
vaginally born
8
psychological neurodevelopmental
8
follow-up study
8

Similar Publications

Collaborative management partnerships (CMPs) between state wildlife authorities and nonprofit conservation organizations to manage protected areas (PAs) have been used increasingly across Sub-Saharan Africa since the 2000s. They aim to attract funding, build capacity, and increase the environmental effectiveness of PAs. Our study documents the rise of CMPs, examines their current extent, and measures their effectiveness in protecting habitats.

View Article and Find Full Text PDF

Objective: To assess factors influencing Neonatal Respiratory Distress Syndrome (RDS) risk, incorporating maternal demographics, behaviors, medical conditions, pregnancy-related factors, and PM2.5 speciation pollutants exposures.

Methods: Using Florida de-identified birth records, logistic regression analyses were conducted to assess associations between maternal exposure to PM2.

View Article and Find Full Text PDF

[18F]Tetrafluoroborate: a new NIS PET/CT radiopharmaceutical. An overview focused on differentiated thyroid cancer.

Eur Thyroid J

January 2025

G Treglia, Repubblica e Cantone Ticino Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

Background: In relapsing differentiated thyroid cancer (DTC), the in vivo evaluation of natrium-iodine symporter (NIS) expression is pivotal in the therapeutic planning and is achieved by [131/123I]Iodine whole-body scan. However, these approaches have low sensitivity due to the low sensitivity due to the low resolution of SPECT. [18F]Tetrafluoroborate (TFB) has been proposed as a viable alternative, which could outperform [131/123I]Iodine scans owing to the superior PET resolution.

View Article and Find Full Text PDF

Preterm births constitute a major public health issue and a chronic, cross-generational condition globally. Psychological and biological factors interact in a way that women from low socio-economic status (SES) are disproportionally affected by preterm delivery and at increased risk for the development of perinatal mental health problems. Low SES constitutes one of the most evident contributors to poor neurodevelopment of preterm infants.

View Article and Find Full Text PDF

Background: Belatacept is approved for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients and is associated with a risk of post-transplant lymphoproliferative disorder (PTLD).

Methods: Data from the Organ Procurement and Transplantation Network were used to examine patterns of belatacept use, describe patient characteristics, and estimate risk of PTLD in EBV-seropositive, kidney-only transplant recipients receiving belatacept- or calcineurin inhibitor (CNI)-based immunosuppression as part of US Food and Drug Administration-mandated safety monitoring.

Results: During the study period (June 15, 2011-June 14, 2016), 94.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!